{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:40:59Z","timestamp":1791319259707,"version":"4.3.1"},"reference-count":182,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":152,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF). Further trials showed efficacy of empagliflozin and dapagliflozin in patients with HF with preserved ejection fraction (HFpEF). These results prompted a broadened recommendation for the SGLT2 inhibitors dapagliflozin or empagliflozin across the whole left ventricular ejection fraction (LVEF) spectrum in the 2023 Focused Update of the ESC HF guidelines and in other international guidelines. In SOLOIST-WHF and EMPULSE, sotagliflozin (enrolling only patients with T2DM) and empagliflozin, respectively, were beneficial when initiated at the end or soon after an episode of decompensated HF. Based on these results and on the early appearance of their beneficial effects, the administration of SGLT2 inhibitors should start early in patients hospitalized for acute HF. Analyses after study drug withdrawal in randomized clinical trials have shown that their benefits may decline rapidly after discontinuation, and thus, persistence of treatment is advised. In EMPACT-MI, empagliflozin did not reduce the primary outcome of cardiovascular (CV) death\/HF hospitalization but reduced first\/recurrent HF hospitalizations. Potential benefits of SGLT2 inhibitors in further specific conditions (i.e., cardiac amyloidosis, grown-up congenital heart disease and paediatric patients with HF) have been reported in observational studies but need confirmation from prospective trials. This scientific statement summarizes current evidence regarding the effects of SGLT2 inhibitors for the prevention and treatment of HF.<\/jats:p>","DOI":"10.1002\/ehf2.15408","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:59:07Z","timestamp":1758268747000},"page":"3806-3825","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure: A Scientific Statement of the HFA and the HFAI"],"prefix":"10.1093","volume":"12","author":[{"given":"Marco","family":"Metra","sequence":"first","affiliation":[{"name":"Cardiology. ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[{"name":"Cardiology. ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]},{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiology. ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Offer","family":"Amir","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, CIBERCV , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boehm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum des Saarlandes, Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]},{"name":"University of Mississippi , Jackson, Mississippi ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. C.C. Iliescu\u2019, University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa A.","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroc\u0142aw Medical University , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute, St George's University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o em Tecnologias e Servi\u00e7os de Sa\u00fade , Porto ,","place":["Portugal"]},{"name":"Servi\u00e7o de Cardiologia, Hospital das For\u00e7as Armadas\u2014P\u00f3lo do Porto , Porto ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroc\u0142aw Medical University , Wroc\u0142aw ,","place":["Poland"]},{"name":"Department of Cardiology, Wroc\u0142aw Medical University , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Scientific Institution of Cardiology and Internal Diseases , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsen","family":"Ristic","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Belgrade , Belgrade ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Roubille","sequence":"additional","affiliation":[{"name":"PhyMedExp, Universit\u00e9 de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Seferovic","sequence":"additional","affiliation":[{"name":"Serbian Academy of Sciences and Arts , Belgrade ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Coats","sequence":"additional","affiliation":[{"name":"Heart Research Institute , Newtown, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medanta , Gurgaon, Haryana ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome , Rome ,","place":["Italy"]},{"name":"IRCCS San Raffaele , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2026080800364751400_ehf215408-bib-0001","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0002","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0003","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0004","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","article-title":"CCS\/CHFS heart failure guidelines update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0005","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0006","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0007","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0008","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0009","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0010","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0011","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0012","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0013","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0014","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"The Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"2026080800364751400_ehf215408-bib-0015","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1093\/eurheartj\/ehae414","article-title":"Heart failure with preserved ejection fraction therapy: Combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"45","author":"Ostrominski","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0016","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0017","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0018","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0019","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2026080800364751400_ehf215408-bib-0020","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0021","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0022","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0023","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0024","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1161\/CIRCULATIONAHA.124.068613","article-title":"Comparative cardiovascular effectiveness of empagliflozin versus dapagliflozin in adults with treated type 2 diabetes: A target trial emulation","volume":"150","author":"Bonnesen","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0025","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.2073","article-title":"Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium\u2013glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58","volume":"23","author":"Zelniker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0026","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0027","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the Task Force on the Management of Cardiovascular Disease in Patients with Diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0028","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","article-title":"Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?","volume":"43","author":"Pitt","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0029","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.121.054442","article-title":"Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes?","volume":"144","author":"Pitt","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0030","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk in Communities (ARIC) study","volume":"18","author":"Kottgen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026080800364751400_ehf215408-bib-0031","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/ejhf.1350","article-title":"Risk factors for incident heart failure in age- and sex-specific strata: A population-based cohort using linked electronic health records","volume":"21","author":"Uijl","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0032","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"9","author":"McMurray","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0033","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jacc.2022.08.772","article-title":"Cardiovascular effects of canagliflozin in relation to renal function and albuminuria","volume":"80","author":"Sarraju","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0034","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ejhf.3292","article-title":"Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0035","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","article-title":"Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: The CREDENCE trial","volume":"148","author":"Januzzi","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0036","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0037","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1093\/eurheartj\/ehab704","article-title":"Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0038","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2026080800364751400_ehf215408-bib-0039","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: Insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0040","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/ejhf.2990","article-title":"Baseline characteristics of patients enrolled in the EMPACT-MI trial","volume":"25","author":"Harrington","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0041","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0042","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ejhf.3560","article-title":"Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)","volume":"27","author":"Carberry","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0043","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: Rationale for and design of the EMPEROR-Preserved trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0044","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0045","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/ejhf.2558","article-title":"Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions","volume":"24","author":"Anker","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0046","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0047","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/eurheartj\/ehad283","article-title":"Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial","volume":"44","author":"Chatur","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0048","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0049","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0050","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/eurheartj\/ehae300","article-title":"Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction","volume":"45","author":"Packer","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0051","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026080800364751400_ehf215408-bib-0052","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: A report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"2026080800364751400_ehf215408-bib-0053","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/CIRCULATIONAHA.123.068089","article-title":"Nature and magnitude of the benefits of dapagliflozin and empagliflozin for heart failure","volume":"149","author":"Cleland","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0054","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0055","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0056","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ejhf.2728","article-title":"Weight change and clinical outcomes in heart failure with reduced ejection fraction: Insights from EMPEROR-Reduced","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0057","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","article-title":"Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: A participant-level pooled analysis of DAPA-HF and DELIVER","volume":"7","author":"Desai","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0058","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jchf.2023.01.018","article-title":"Recency of heart failure hospitalization, outcomes, and the effect of empagliflozin: An EMPEROR-Pooled analysis","volume":"11","author":"Ferreira","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0059","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","article-title":"Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: Insights from DAPA-HF and DELIVER","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0060","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehad276","article-title":"Heart failure, peripheral artery disease, and dapagliflozin: A patient-level meta-analysis of DAPA-HF and DELIVER","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0061","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchf.2023.06.036","article-title":"Efficacy and safety of empagliflozin according to background diuretic use in HFrEF: Post-hoc analysis of EMPEROR-Reduced","volume":"12","author":"Dhingra","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0062","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ejhf.3000","article-title":"Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER","volume":"25","author":"Butt","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0063","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jchf.2022.11.014","article-title":"Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum","volume":"11","author":"Butt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0064","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus: Results from the CANVAS Program","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0065","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0066","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jacc.2022.07.021","article-title":"Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction","volume":"80","author":"Cunningham","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0067","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S2213-8587(22)00308-4","article-title":"Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): A subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"Inzucchi","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080800364751400_ehf215408-bib-0068","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.062918","article-title":"Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: A prespecified analysis of the DELIVER trial","volume":"147","author":"Kondo","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0069","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026080800364751400_ehf215408-bib-0070","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1038\/s41591-022-02102-9","article-title":"Dapagliflozin in heart failure with improved ejection fraction: A prespecified analysis of the DELIVER trial","volume":"28","author":"Vardeny","year":"2022","journal-title":"Nat Med"},{"key":"2026080800364751400_ehf215408-bib-0071","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/ejhf.3001","article-title":"Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial","volume":"25","author":"Pabon","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0072","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2213-8587(21)00292-8","article-title":"Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): A post-hoc analysis of a randomised, double-blind trial","volume":"10","author":"Verma","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080800364751400_ehf215408-bib-0073","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ejhf.2722","article-title":"Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan","volume":"24","author":"Yang","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0074","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: Definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0075","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jchf.2025.03.010","article-title":"Diuretic de-escalation in response to HF therapy: Are we closer to reduced reliance on diuretics?","volume":"13","author":"Biegus","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0076","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","article-title":"Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF","volume":"142","author":"Jackson","year":"2020","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0077","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0078","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/ejhf.2831","article-title":"Health status across major subgroups of patients with heart failure and preserved ejection fraction","volume":"25","author":"Siddiqi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0079","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","article-title":"Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: Pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials","volume":"16","author":"Nassif","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0080","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/CIRCULATIONAHA.122.063263","article-title":"Racial differences in quality of life in patients with heart failure treated with sodium\u2013glucose cotransporter 2 inhibitors: A patient-level meta-analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF trials","volume":"148","author":"Gupta","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0081","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0082","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjcvp\/pvad088","article-title":"Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: A comprehensive systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Oriecuia","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080800364751400_ehf215408-bib-0083","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0084","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1161\/CIRCULATIONAHA.124.072158","article-title":"Patient-reported outcomes as end points in heart failure trials","volume":"151","author":"Butler","year":"2025","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0085","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1161\/CIRCULATIONAHA.124.070411","article-title":"Evidence generation and implementation of transcatheter interventions for atrioventricular valvular heart disease in heart failure: Current status and future directions","volume":"151","author":"Metra","year":"2025","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0086","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.123.065061","article-title":"Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: The DETERMINE randomized clinical trials","volume":"149","author":"McMurray","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0087","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010633","article-title":"Effect of dapagliflozin on 6-minute walk distance in heart failure with preserved ejection fraction: PRESERVED-HF","volume":"16","author":"Lewis","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0088","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: The CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0089","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.124.068788","article-title":"Dapagliflozin enhances arterial and venous compliance during exercise in heart failure with preserved ejection fraction: Insights from the CAMEO-DAPA trial","volume":"150","author":"Tada","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0090","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehaf027","article-title":"Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: The CAMEO-DAPA trial","volume":"46","author":"Doi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0091","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0092","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: Results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0093","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0094","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.3112","article-title":"The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry","volume":"26","author":"Tomasoni","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0095","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"2026080800364751400_ehf215408-bib-0096","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: The PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0097","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: The DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0098","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0099","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"2026080800364751400_ehf215408-bib-0100","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0101","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0102","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1056\/NEJMc2502743","article-title":"Tirzepatide for heart failure and obesity. Reply","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0103","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0104","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.053709","article-title":"Are SGLT2 inhibitors new hypertension drugs?","volume":"143","author":"Kario","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0105","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: Insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0106","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.123.065254","article-title":"Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial","volume":"148","author":"Ostrominski","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0107","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/eurheartj\/ehae938","article-title":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: The EMPEROR-Preserved trial","volume":"46","author":"Bohm","year":"2025","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0108","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0109","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","article-title":"Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure","volume":"78","author":"Bohm","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0110","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","article-title":"Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0111","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: The EMPEROR-Preserved trial","volume":"44","author":"Bhm","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0112","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0113","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0114","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/ejhf.3618","article-title":"Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC","volume":"27","author":"Skouri","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0115","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0116","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0117","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0118","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0119","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0120","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium\u2013glucose co-transporter-2 inhibitors in heart failure: A meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0121","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0122","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/ejhf.2578","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced","volume":"24","author":"Zannad","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0123","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: Insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0124","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.jacc.2023.08.026","article-title":"Dapagliflozin in patients with heart failure and deterioration in renal function","volume":"82","author":"Chatur","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0125","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/ejhf.2922","article-title":"Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial","volume":"25","author":"Bohm","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0126","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.2337\/dc20-1402","article-title":"Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy","volume":"43","author":"Docherty","year":"2020","journal-title":"Diabetes Care"},{"key":"2026080800364751400_ehf215408-bib-0127","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.jacc.2021.08.064","article-title":"In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction","volume":"78","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0128","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/ejhf.2888","article-title":"Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0129","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ejhf.2915","article-title":"Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial","volume":"25","author":"Chatur","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0130","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of sotagliflozin on early mortality and heart failure-related events: A post hoc analysis of SOLOIST-WHF","volume":"11","author":"Pitt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0131","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026080800364751400_ehf215408-bib-0132","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: Results from the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0133","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0134","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/ejhf.2968","article-title":"Similarities and distinctions between acetazolamide and sodium\u2013glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE","volume":"25","author":"Packer","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0135","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0136","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0137","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/ejhf.2967","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0138","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: Diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0139","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0140","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0141","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: Data from the Empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0142","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0143","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1093\/eurheartj\/ehad617","article-title":"Acute heart failure: Current pharmacological treatment and perspectives","volume":"44","author":"Deniau","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0144","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0145","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ejhf.3464","article-title":"Timing of sodium\u2013glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: A population-based cohort study","volume":"27","author":"Wu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0146","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: A prospective randomized controlled study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0147","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ahj.2022.12.005","article-title":"Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial","volume":"257","author":"Horiuchi","year":"2023","journal-title":"Am Heart J"},{"key":"2026080800364751400_ehf215408-bib-0148","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ejhf.2370","article-title":"Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial","volume":"24","author":"Amat-Santos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0149","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080800364751400_ehf215408-bib-0150","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0151","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0152","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","article-title":"Early clinical experience with dapagliflozin in children with heart failure","volume":"44","author":"Newland","year":"2023","journal-title":"Pediatr Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0153","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1093201","article-title":"The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease","volume":"10","author":"Neijenhuis","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026080800364751400_ehf215408-bib-0154","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0155","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0156","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ehf2.14186","article-title":"Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction","volume":"10","author":"Ortega-Paz","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0157","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0158","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008365","article-title":"Enhanced expression and function of renal SGLT2 (sodium-glucose cotransporter 2) in heart failure: Role of renal nerves","volume":"14","author":"Katsurada","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0159","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ejhf.2884","article-title":"Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study","volume":"25","author":"Pascual-Figal","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0160","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0161","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/ehjcvp\/pvaf003","article-title":"Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography\u2014A subanalysis of the EMPAG-HF trial","volume":"11","author":"Bogoviku","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080800364751400_ehf215408-bib-0162","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0163","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0164","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1161\/CIRCULATIONAHA.122.062769","article-title":"Empagliflozin and left ventricular remodeling in people without diabetes: Primary results of the EMPA-HEART 2 CardioLink-7 randomized clinical trial","volume":"147","author":"Connelly","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0165","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ejhf.3129","article-title":"The effect of sodium\u2013glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis","volume":"26","author":"Usman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0166","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: Mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080800364751400_ehf215408-bib-0167","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: Findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0168","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1161\/CIRCULATIONAHA.122.062021","article-title":"Assessment of cardiac energy metabolism, function, and physiology in patients with heart failure taking empagliflozin: The randomized, controlled EMPA-VISION trial","volume":"147","author":"Hundertmark","year":"2023","journal-title":"Circulation"},{"key":"2026080800364751400_ehf215408-bib-0169","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ejhf.1732","article-title":"Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium\u2013glucose cotransporter 2 inhibitors","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0170","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","article-title":"Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"7","author":"Vaduganathan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0171","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ejhf.2137","article-title":"Sodium\u2013glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: Rationale for and design of the EMPULSE trial","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0172","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026080800364751400_ehf215408-bib-0173","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012263","article-title":"Home-time is good, but feeling well is better. Patient-journey and quality home-time as end points in heart failure trials and registries","volume":"17","author":"Cleland","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0174","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026080800364751400_ehf215408-bib-0175","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40265-018-0901-y","article-title":"The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus","volume":"78","author":"Fattah","year":"2018","journal-title":"Drugs"},{"key":"2026080800364751400_ehf215408-bib-0176","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J Card Fail"},{"key":"2026080800364751400_ehf215408-bib-0177","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ejhf.2864","article-title":"Potential global impact of sodium\u2013glucose cotransporter-2 inhibitors in heart failure","volume":"25","author":"Talha","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0178","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamacardio.2022.4348","article-title":"Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US","volume":"8","author":"Talha","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026080800364751400_ehf215408-bib-0179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014Inertia, titration, and discontinuation: A multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0180","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ejhf.2971","article-title":"Real-world use of sodium\u2013glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry","volume":"25","author":"Stolfo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0181","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080800364751400_ehf215408-bib-0182","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ejhf.3416","article-title":"Differences in heart failure with preserved ejection fraction management between care providers: An international survey","volume":"27","author":"Guidetti","year":"2025","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/3806\/66968035\/eschf_12_6_3806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/3806\/66968035\/eschf_12_6_3806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:37:20Z","timestamp":1786163840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/3806\/8488155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":182,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,19]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15408","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}